Tozorakimab clinical trials
Also written MEDI3506.
How each study uses tozorakimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tozorakimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
13 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test tozorakimab, phase 3 first.
- Nov 2027Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenPhase 3 · AstraZeneca
- Jun 2027Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsPhase 2 · AstraZeneca
Studies
Open first, then newest update. How each study uses tozorakimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenRecruitingPhase 3AstraZenecaNCT05624450Written as Tozorakimab
- Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsRecruitingPhase 2AstraZenecaNCT06932263Written as Tozorakimab
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompletedPhase 3AstraZenecaNCT06040086Written as Tozorakimab
- A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated EosinophilsCompletedPhase 2AstraZenecaNCT06897748Written as Tozorakimab
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsCompletedPhase 3AstraZenecaNCT05166889Written as Tozorakimab
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.CompletedPhase 3AstraZenecaNCT05158387Written as Tozorakimab
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic BronchitisCompletedPhase 2AstraZenecaNCT04631016Written as Tozorakimab
- A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy VolunteersCompletedPhase 1AstraZenecaNCT06304961Written as Tozorakimab
- A Phase 2b Diabetic Kidney Disease StudyCompletedPhase 2AstraZenecaNCT04170543Written as MEDI3506
- Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe AsthmaCompletedPhase 2AstraZenecaNCT04570657Written as MEDI3506
- Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic DermatitisCompletedPhase 2AstraZenecaNCT04212169Written as MEDI3506
- Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese ParticipantsCompletedPhase 1AstraZenecaNCT05070312Written as MEDI3506
- Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese ParticipantsCompletedPhase 1MedImmune LLCNCT03096795Written as MEDI3506
Given beside what is tested · 1 — tozorakimab is usual care or a partner of the new treatment
Codes
What other systems call tozorakimab · ClinicalTrials.gg INT017477
- UNII (FDA) OHZ2MEL7FDTOZORAKIMABOne source FDA
- NCI Thesaurus C179129TozorakimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OHZ2MEL7FD | TOZORAKIMAB | One source FDA |
| NCI Thesaurus | C179129 | Tozorakimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.